Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans
Datos Bibliográficos
| ID | 15808487 |
|---|---|
| Autores | Yonghong Li (0000-0002-2623-357X, Quest Diagnostics (United States), autor de correspondencia), Avneet K Heer (Haystack Oncology, Baltimore, Maryland), Hillary S Sloane (0000-0002-5046-4589, Haystack Oncology, Baltimore, Maryland), Daniel L Edelstein (0000-0002-9498-1764, Haystack Oncology, Baltimore, Maryland), Jeanne Tie (0000-0001-9244-2057, Walter and Eliza Hall Institute of Medical Research), Peter Gibbs (0000-0003-1423-4484, Walter and Eliza Hall Institute of Medical Research), Afsaneh Barzi (0000-0002-0032-2988, University of Southern California) |
| Año | 2024 |
| Volumen | 5 |
| Número | 5 |
| Páginas | e241270-e241270 |
| Fecha de publicación | 2024-05-31 |
| Peer Reviewed | Sí |
| Open Access | Sí |
| Tipo | ARTICLE |
| Revista | JAMA Health Forum (JOURNAL) |
| Identificadores de la revista | ISSN: 2689-0186 • E-ISSN: 2689-0186 |
| Editorial | American Medical Association (PUBLISHER • US) |
| DOI | 10.1001/jamahealthforum.2024.1270 |
| PMID | 38819797 |
| OpenAlex | W4399210103 |
| Idioma | EN |
| Referencias citadas | 28 |
Use of tumor-informed ctDNA testing to guide adjuvant chemotherapy in postsurgery patients with stage II colon cancer was projected to result in cost savings for both commercial and Medicare Advantage payers. Adoption of ctDNA testing is therefore advantageous from a budgetary perspective
Cancer · Colorectal cancer · Environmental health · Health care · Health plan · Medicare Advantage · Population · Cancer Genomics and Diagnostics · Genetic factors in colorectal cancer · Medicine · Pancreatic and Hepatic Oncology Research · Emergency Medicine · Internal Medicine · Oncology
| Velocidad de citación | historical |
|---|---|
| Altamente citado | No |